Evidence map›Paper›PMID 29454314›Full record

ArticleBMC cancer2018

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.

Duneesha de Fonseka, David T Arnold, Louise Stadon, Anna Morley, Emma Keenan, Michael Darby, Lynne Armstrong, Paul Virgo, Nick A Maskell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Duneesha de FonsekaAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
David T ArnoldAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK. arnold.dta@gmail.com.
Louise StadonAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Anna MorleyAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Emma KeenanAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Michael DarbyDepartment of Radiology, Southmead Hospital, North Bristol NHS Trust, Bristol, BS10 5NB, UK.
Lynne ArmstrongDepartment of Radiology, University Hospitals Bristol, Bristol, BS2 8HW, UK.
Paul VirgoAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Nick A MaskellAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Learning and Research Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
Southmead Hospital · GBUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in the assessment of treatment response during chemotherapy but has never been assessed in the longer term follow up of patients.

methodsThis is a single centre study of consecutive patients diagnosed with MPM who received chemotherapy or best supportive care (BSC). Serum mesothelin measurements with paired 6 monthly CT scans were performed following the completion of chemotherapy, or from baseline in the BSC group. Changes in mesothelin were correlated with radiological progression and overall survival.

resultsForty-one patients with MPM were recruited and followed up for a minimum of 12 months (range 12-21 months). The majority of patients (n = 23) received chemotherapy with pemetrexed and cisplatin. Across the cohort a 10% rise in serum mesothelin could predict radiological progression with a sensitivity of 96% (IQR; 79-100) and specificity of 74% (IQR; 50-91). Sensitivity fell to 80% in sarcomatoid only disease. Patients with a rising mesothelin at 6 months had significantly worse overall survival (175 days) compared to stable/falling levels (448 days) (p = 0.003).

conclusionsThis is the first study to assess serum mesothelin's ability to detect progression of MPM following chemotherapy or during BSC. A 10% rise in serum mesothelin level showed excellent sensitivity at predicting progressive disease. Mesothelin measurement has several advantages over serial CT imaging including reducing hospital visits and cost.

Indexed as

Biomarkers, TumorAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionFemaleFollow-Up StudiesGPI-Linked ProteinsHumansLung NeoplasmsMaleMesothelinMesotheliomaMesothelioma, MalignantMiddle AgedPrognosisBiomarkers, TumorGPI-Linked ProteinsMesothelinBiomarkersMesothelinMesotheliomaMonitoring

Identifiers

PMID29454314
PMCPMC5816389
OpenAlexW2796229527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.